Comparative efficacy and acceptability of treatments for restless legs syndrome in end-stage renal disease: a systematic review and network meta-analysis

被引:12
|
作者
Huang, Chien-Wei [1 ,2 ]
Lee, Min-Jing [3 ]
Wang, Liang-Jen [3 ]
Lee, Po-Tsang [1 ,2 ]
Tu, Yu-Kang [4 ,5 ,6 ]
Hsu, Chih-Wei [7 ]
Lin, Pao-Yen [7 ,8 ]
机构
[1] Kaohsiung Vet Gen Hosp, Dept Med, Div Nephrol, Kaohsiung, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan
[3] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Dept Child & Adolescent Psychiat, Coll Med, Kaohsiung, Taiwan
[4] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Coll Publ Hlth, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Dent, Taipei, Taiwan
[7] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Dept Psychiat, Coll Med, Kaohsiung, Taiwan
[8] Kaohsiung Chang Gung Mem Hosp, Inst Translat Res Biomed Sci, Kaohsiung, Taiwan
关键词
combination therapy; end-stage renal disease; gabapentin; network meta-analysis; restless legs syndrome; NEAR-INFRARED LIGHT; HEMODIALYSIS-PATIENTS; DOUBLE-BLIND; CARDIOVASCULAR RISK; DIALYSIS PATIENTS; CONTROLLED-TRIAL; SINGLE-BLIND; SYNDROME RLS; EXERCISE; IRON;
D O I
10.1093/ndt/gfz097
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Restless legs syndrome (RLS) is common in endstage renal disease (ESRD) patients and impairs health and quality of life significantly. However, the optimal treatment of RLS in ESRD patients is uncertain and less studied compared with idiopathic RLS patients. Methods. We conducted a systematic review and network meta-analysis to compare the efficacy and acceptability of treatments for RLS in ESRD patient& Randomized controlled trials (RCTs) by February 2019 in the PubMed, Cochrane Library, Embase and ClinicalTrials.gov were reviewed. RLS severity reduction was treated as treatment efficacy, and adverse events were treated as acceptable. Both outcomes were appraised using a random effects model expressed as standardized mean differences and odds ratios with 95% confidence intervals (CIs), respectively, and were ranked using surface under the cumulative ranking curve (SUCRA) probabilities to obtain a hierarchy of interventions. Results. A total of 12 RCTs were included, comprising 9 interventions and 498 participants. All the interventions significantly improved RLS severity without critical side effects compared with placebo. Gabapentin achieved the greatest decrease of RLS severity [standardized mean difference (SMD) = 1.95, 95% CI 0.81-3.09 (SUCRA: 79.3%)], despite its frequent adverse events [SMD = 0.18, 95% CI 0.02-150 (19.9%)]. The combination therapy of exercise plus dopamine agonist had better efficacy [SMD = 1.60, 95% CI 0.08-3.12 (59.8%)] and acceptability [SMD = 1.41, 95% CI 0.01-142.53 (63.9%)] compared with that of vitamin C plus vitamin E [SMD = 150, 95% CI 0.47-2.54 (56.6%); SMD = 0.32, 95% CI 0.04-2.86 (325%)]. Conclusions. This network meta-analysis supports that gabapentin is the most effective treatment for RLS in ESRD patients. Exercise plus dopamine agonist is a favorable combination therapy concerning side effects. Future large RCTs with long-term treatment outcomes are necessary.
引用
收藏
页码:1609 / 1618
页数:10
相关论文
共 50 条
  • [1] Comparative Efficacy of Treatments for Restless Legs Syndrome: A Network Meta-analysis
    Alghothani, Lana
    Iftikhar, Imran
    [J]. CHEST, 2016, 150 (04) : 1267A - 1267A
  • [2] Pharmacological and non-pharmacological treatments for restless legs syndrome in end-stage kidney disease: a systematic review and component network meta-analysis
    Chen, Jia-Jin
    Lee, Tao Han
    Tu, Yu-Kang
    Kuo, George
    Yang, Huang-Yu
    Yen, Chieh-Li
    Fan, Pei-Chun
    Chang, Chih-Hsiang
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (10) : 1982 - 1992
  • [3] Restless legs syndrome in end-stage renal disease
    Gigli, GL
    Adorati, M
    Dolso, P
    Piani, A
    Valente, M
    Brotini, S
    Budai, R
    [J]. SLEEP MEDICINE, 2004, 5 (03) : 309 - 315
  • [4] Restless legs syndrome in end-stage renal disease
    Winkelman, JW
    Chertow, GM
    Lazarus, JM
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (03) : 372 - 378
  • [5] The Efficacy and Safety of Pharmacological Treatments for Restless Legs Syndrome: Systemic Review and Network Meta-Analysis
    Zhou, Xuan
    Du, Juncong
    Liang, Yi
    Dai, Chengcheng
    Zhao, Lili
    Liu, Xi
    Tan, Changhong
    Mo, Lijuan
    Chen, Lifen
    [J]. FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [6] Prevalence of metabolic syndrome in patients with end-stage renal disease: a systematic review and meta-analysis
    Qiufeng Du
    Yunlan Jiang
    Yaxin Liu
    [J]. International Urology and Nephrology, 2024, 56 (3) : 1057 - 1069
  • [7] Prevalence of metabolic syndrome in patients with end-stage renal disease: a systematic review and meta-analysis
    Du, Qiufeng
    Jiang, Yunlan
    Liu, Yaxin
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2024, 56 (03) : 1057 - 1069
  • [8] Clinical management of restless legs syndrome in end-stage renal disease patients
    Sahli, Zeyad T.
    Jo, Jae
    Mousa, Shaker A.
    Tarazi, Frank I.
    [J]. CNS SPECTRUMS, 2017, 22 (01) : 14 - 21
  • [9] Restless legs syndrome in end-stage renal disease: a multicenter study in Taiwan
    Lin, C. -H.
    Wu, V. -C.
    Li, W. -Y.
    Sy, H. -N.
    Wu, S. -L.
    Chang, C. -C.
    Chiu, P. -F.
    Lion, H. -H.
    Lin, C. -Y.
    Chang, H. -W.
    Lin, S. -Y.
    Wu, K. -D.
    Chen, Y. -M.
    Wu, R. -M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (07) : 1025 - E89
  • [10] Prevalence of frailty in end-stage renal disease: a systematic review and meta-analysis
    Kojima, Gotaro
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (11) : 1989 - 1997